Frank Scott
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 28 | 2026 | 366 | 8.250 |
Why?
| | Crohn Disease | 16 | 2025 | 262 | 5.400 |
Why?
| | Gastrointestinal Agents | 7 | 2025 | 65 | 3.280 |
Why?
| | Gastroenterology | 7 | 2025 | 191 | 2.050 |
Why?
| | Colitis, Ulcerative | 9 | 2025 | 149 | 2.010 |
Why?
| | Infliximab | 10 | 2022 | 111 | 1.500 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 55 | 1.420 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 840 | 1.220 |
Why?
| | Tissue Adhesions | 3 | 2021 | 34 | 1.210 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 487 | 1.090 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1225 | 1.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 1005 | 1.030 |
Why?
| | Algorithms | 7 | 2026 | 1868 | 0.970 |
Why?
| | Intestine, Small | 2 | 2021 | 168 | 0.930 |
Why?
| | Patient Acceptance of Health Care | 5 | 2026 | 895 | 0.910 |
Why?
| | Biological Products | 4 | 2026 | 258 | 0.890 |
Why?
| | Ustekinumab | 2 | 2025 | 17 | 0.870 |
Why?
| | JC Virus | 2 | 2015 | 23 | 0.850 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 38 | 0.830 |
Why?
| | Azathioprine | 5 | 2021 | 44 | 0.780 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 59 | 0.770 |
Why?
| | Humans | 91 | 2026 | 147306 | 0.750 |
Why?
| | Abdomen | 2 | 2021 | 142 | 0.720 |
Why?
| | Abdominal Abscess | 1 | 2022 | 28 | 0.720 |
Why?
| | Drug Monitoring | 1 | 2026 | 402 | 0.710 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 351 | 0.700 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 139 | 0.660 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2974 | 0.640 |
Why?
| | Splints | 1 | 2020 | 14 | 0.640 |
Why?
| | Postoperative Complications | 3 | 2021 | 3022 | 0.630 |
Why?
| | Retrospective Studies | 27 | 2026 | 17561 | 0.630 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 25 | 0.630 |
Why?
| | Antibodies, Viral | 2 | 2015 | 687 | 0.620 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1940 | 0.620 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 28 | 0.610 |
Why?
| | Radius Fractures | 1 | 2020 | 69 | 0.590 |
Why?
| | Barrett Esophagus | 4 | 2023 | 172 | 0.590 |
Why?
| | Biomedical Research | 2 | 2019 | 723 | 0.580 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 448 | 0.580 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 126 | 0.570 |
Why?
| | Spondylarthritis | 3 | 2025 | 50 | 0.570 |
Why?
| | Colonoscopy | 7 | 2024 | 267 | 0.550 |
Why?
| | Intestinal Fistula | 1 | 2018 | 18 | 0.540 |
Why?
| | Drug Utilization | 1 | 2019 | 171 | 0.540 |
Why?
| | Colonic Diseases | 1 | 2018 | 37 | 0.530 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 272 | 0.530 |
Why?
| | Adult | 37 | 2026 | 41406 | 0.530 |
Why?
| | Tuberculin Test | 1 | 2017 | 36 | 0.530 |
Why?
| | Health Resources | 1 | 2019 | 133 | 0.530 |
Why?
| | Hospitalization | 4 | 2026 | 2496 | 0.530 |
Why?
| | Pericardium | 1 | 2018 | 59 | 0.530 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 654 | 0.520 |
Why?
| | Biological Factors | 2 | 2023 | 39 | 0.510 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 102 | 0.510 |
Why?
| | Models, Statistical | 2 | 2019 | 677 | 0.500 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 70 | 0.490 |
Why?
| | Male | 48 | 2026 | 73954 | 0.480 |
Why?
| | Mass Screening | 4 | 2021 | 1375 | 0.480 |
Why?
| | Middle Aged | 37 | 2026 | 36821 | 0.480 |
Why?
| | Time-to-Treatment | 2 | 2019 | 258 | 0.470 |
Why?
| | Remission Induction | 3 | 2025 | 310 | 0.460 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 877 | 0.460 |
Why?
| | Treatment Outcome | 14 | 2025 | 11947 | 0.450 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1514 | 0.450 |
Why?
| | Natalizumab | 1 | 2015 | 41 | 0.440 |
Why?
| | Radius | 1 | 2015 | 53 | 0.440 |
Why?
| | Heart Diseases | 1 | 2018 | 341 | 0.420 |
Why?
| | Fracture Fixation | 1 | 2015 | 80 | 0.420 |
Why?
| | Models, Theoretical | 1 | 2018 | 563 | 0.420 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 324 | 0.410 |
Why?
| | Age Factors | 5 | 2025 | 3372 | 0.410 |
Why?
| | Female | 44 | 2026 | 80081 | 0.390 |
Why?
| | Practice Patterns, Physicians' | 3 | 2024 | 1379 | 0.390 |
Why?
| | Leukocyte L1 Antigen Complex | 2 | 2026 | 41 | 0.390 |
Why?
| | Markov Chains | 3 | 2020 | 132 | 0.380 |
Why?
| | Aged | 27 | 2024 | 26516 | 0.380 |
Why?
| | Lymphoma | 1 | 2014 | 253 | 0.360 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1046 | 0.360 |
Why?
| | Risk Factors | 17 | 2025 | 11017 | 0.360 |
Why?
| | Adalimumab | 3 | 2021 | 54 | 0.360 |
Why?
| | Communicable Diseases | 1 | 2014 | 166 | 0.350 |
Why?
| | Feces | 3 | 2026 | 500 | 0.340 |
Why?
| | Professional Competence | 1 | 2012 | 91 | 0.340 |
Why?
| | Gastroenterologists | 2 | 2022 | 21 | 0.340 |
Why?
| | United Kingdom | 5 | 2021 | 391 | 0.340 |
Why?
| | Patient Discharge | 2 | 2023 | 1002 | 0.340 |
Why?
| | Disease Management | 3 | 2021 | 654 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 648 | 0.320 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 347 | 0.320 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.320 |
Why?
| | Research Design | 2 | 2019 | 1158 | 0.320 |
Why?
| | Cohort Studies | 10 | 2025 | 6099 | 0.320 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 237 | 0.310 |
Why?
| | Adenoma | 3 | 2024 | 219 | 0.310 |
Why?
| | Research Personnel | 1 | 2012 | 187 | 0.310 |
Why?
| | Colonic Polyps | 2 | 2024 | 89 | 0.300 |
Why?
| | Fractures, Bone | 1 | 2015 | 433 | 0.300 |
Why?
| | United States | 17 | 2025 | 16313 | 0.290 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1344 | 0.290 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 261 | 0.280 |
Why?
| | Janus Kinase Inhibitors | 2 | 2025 | 28 | 0.280 |
Why?
| | Pediatric Obesity | 1 | 2016 | 640 | 0.270 |
Why?
| | Skin Neoplasms | 1 | 2016 | 865 | 0.270 |
Why?
| | Societies, Medical | 4 | 2025 | 914 | 0.270 |
Why?
| | Incidence | 8 | 2021 | 2954 | 0.260 |
Why?
| | Quality of Life | 2 | 2021 | 3246 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1777 | 0.260 |
Why?
| | Electronic Health Records | 6 | 2022 | 1214 | 0.250 |
Why?
| | Consensus | 2 | 2025 | 476 | 0.240 |
Why?
| | Databases, Factual | 7 | 2018 | 1504 | 0.240 |
Why?
| | Mortality | 2 | 2020 | 382 | 0.240 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 42 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 1166 | 0.230 |
Why?
| | Radiography | 2 | 2020 | 862 | 0.220 |
Why?
| | Population Surveillance | 2 | 2021 | 486 | 0.220 |
Why?
| | Adenocarcinoma | 3 | 2022 | 928 | 0.220 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 88 | 0.220 |
Why?
| | Antifungal Agents | 2 | 2016 | 153 | 0.220 |
Why?
| | Referral and Consultation | 2 | 2023 | 886 | 0.210 |
Why?
| | Evidence-Based Medicine | 2 | 2025 | 742 | 0.210 |
Why?
| | Case-Control Studies | 8 | 2021 | 3660 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2020 | 8432 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 951 | 0.210 |
Why?
| | Recurrence | 5 | 2021 | 1151 | 0.200 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 60 | 0.200 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 6164 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 92 | 0.190 |
Why?
| | C-Reactive Protein | 1 | 2026 | 430 | 0.190 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 773 | 0.190 |
Why?
| | Obesity | 1 | 2017 | 3149 | 0.190 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 16 | 0.190 |
Why?
| | Colectomy | 2 | 2021 | 107 | 0.190 |
Why?
| | Protective Factors | 2 | 2021 | 102 | 0.190 |
Why?
| | Models, Economic | 2 | 2020 | 64 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2018 | 537 | 0.190 |
Why?
| | Logistic Models | 6 | 2018 | 2142 | 0.190 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 277 | 0.190 |
Why?
| | Comparative Effectiveness Research | 2 | 2024 | 170 | 0.180 |
Why?
| | Cellulitis | 1 | 2022 | 54 | 0.180 |
Why?
| | Medical Marijuana | 1 | 2024 | 122 | 0.180 |
Why?
| | Prognosis | 4 | 2019 | 4384 | 0.180 |
Why?
| | Odds Ratio | 4 | 2018 | 1084 | 0.180 |
Why?
| | Necrosis | 1 | 2022 | 245 | 0.170 |
Why?
| | Amputation, Traumatic | 1 | 2021 | 21 | 0.170 |
Why?
| | Finger Injuries | 1 | 2021 | 26 | 0.170 |
Why?
| | Insurance, Health | 1 | 2024 | 321 | 0.170 |
Why?
| | Rectal Fistula | 1 | 2021 | 27 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2021 | 841 | 0.160 |
Why?
| | Aftercare | 1 | 2023 | 225 | 0.160 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 347 | 0.160 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 947 | 0.160 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 67 | 0.160 |
Why?
| | Prevalence | 4 | 2025 | 2889 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5478 | 0.160 |
Why?
| | Cystectomy | 2 | 2017 | 44 | 0.160 |
Why?
| | Utilization Review | 1 | 2020 | 39 | 0.160 |
Why?
| | Esophagoscopy | 2 | 2022 | 223 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 40 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 112 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1598 | 0.150 |
Why?
| | Carcinoma | 1 | 2021 | 231 | 0.150 |
Why?
| | Bone Density | 1 | 2023 | 493 | 0.150 |
Why?
| | Bone Plates | 1 | 2020 | 81 | 0.150 |
Why?
| | Metagenomics | 1 | 2021 | 151 | 0.150 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 42 | 0.150 |
Why?
| | Tryptophan | 1 | 2021 | 183 | 0.150 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 343 | 0.150 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 121 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1107 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 2017 | 0.150 |
Why?
| | Hospitals | 2 | 2021 | 740 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2024 | 389 | 0.140 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 259 | 0.140 |
Why?
| | Deglutition Disorders | 1 | 2021 | 159 | 0.140 |
Why?
| | Chronic Disease | 2 | 2022 | 1845 | 0.140 |
Why?
| | Child | 6 | 2023 | 22980 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2023 | 298 | 0.140 |
Why?
| | Metabolomics | 2 | 2022 | 737 | 0.140 |
Why?
| | Diverticulum | 1 | 2018 | 15 | 0.140 |
Why?
| | Hematemesis | 1 | 2018 | 4 | 0.140 |
Why?
| | Job Satisfaction | 1 | 2021 | 238 | 0.140 |
Why?
| | Health Care Costs | 1 | 2021 | 428 | 0.130 |
Why?
| | Symptom Assessment | 2 | 2017 | 137 | 0.130 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 299 | 0.130 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 440 | 0.130 |
Why?
| | Fracture Fixation, Internal | 1 | 2020 | 214 | 0.130 |
Why?
| | Intestines | 1 | 2021 | 356 | 0.130 |
Why?
| | Infant | 5 | 2020 | 10195 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 74 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2018 | 306 | 0.130 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 40 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1183 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 697 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2021 | 625 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 11 | 0.120 |
Why?
| | Budesonide | 1 | 2016 | 49 | 0.120 |
Why?
| | Risk Assessment | 3 | 2016 | 3784 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 300 | 0.120 |
Why?
| | Itraconazole | 1 | 2016 | 8 | 0.120 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 61 | 0.120 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 24 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 237 | 0.120 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 66 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2020 | 590 | 0.110 |
Why?
| | Cysts | 1 | 2016 | 112 | 0.110 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 103 | 0.110 |
Why?
| | Epiphyses | 1 | 2015 | 25 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2016 | 120 | 0.110 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1167 | 0.110 |
Why?
| | Data Accuracy | 1 | 2015 | 65 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 6011 | 0.110 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 308 | 0.110 |
Why?
| | Child, Preschool | 5 | 2016 | 12017 | 0.110 |
Why?
| | Polypharmacy | 1 | 2015 | 95 | 0.110 |
Why?
| | Psoriasis | 1 | 2016 | 115 | 0.110 |
Why?
| | Elbow Joint | 1 | 2015 | 73 | 0.110 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 64 | 0.110 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 201 | 0.100 |
Why?
| | Microbiota | 1 | 2022 | 736 | 0.100 |
Why?
| | Adolescent | 7 | 2019 | 22826 | 0.100 |
Why?
| | Interferon-gamma | 1 | 2017 | 786 | 0.100 |
Why?
| | Prescription Drugs | 1 | 2015 | 111 | 0.100 |
Why?
| | Dilatation | 1 | 2014 | 73 | 0.100 |
Why?
| | Cholesterol | 1 | 2016 | 410 | 0.100 |
Why?
| | Neoplasms | 2 | 2023 | 2946 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2021 | 490 | 0.100 |
Why?
| | Young Adult | 7 | 2019 | 14437 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2016 | 261 | 0.100 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 167 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 218 | 0.100 |
Why?
| | Streptococcal Infections | 1 | 2016 | 179 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2014 | 149 | 0.100 |
Why?
| | Foreign Bodies | 1 | 2014 | 110 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 673 | 0.090 |
Why?
| | Disease Progression | 2 | 2021 | 2892 | 0.090 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 506 | 0.090 |
Why?
| | Reoperation | 1 | 2015 | 644 | 0.090 |
Why?
| | Primary Health Care | 2 | 2022 | 1760 | 0.090 |
Why?
| | Diabetes Complications | 1 | 2013 | 225 | 0.090 |
Why?
| | Epidemiology | 1 | 2012 | 32 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2434 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 83 | 0.090 |
Why?
| | Patient Readmission | 1 | 2017 | 777 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 346 | 0.090 |
Why?
| | Endoscopy | 1 | 2014 | 322 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 350 | 0.080 |
Why?
| | Age Distribution | 1 | 2012 | 406 | 0.080 |
Why?
| | Biomarkers | 2 | 2020 | 4354 | 0.080 |
Why?
| | Time Factors | 5 | 2021 | 7173 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2133 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 961 | 0.080 |
Why?
| | Veterans | 1 | 2021 | 1675 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 8166 | 0.070 |
Why?
| | Drug Prescriptions | 2 | 2024 | 293 | 0.070 |
Why?
| | Medicare | 3 | 2021 | 915 | 0.070 |
Why?
| | Laparoscopy | 1 | 2012 | 486 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1492 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2416 | 0.060 |
Why?
| | Pennsylvania | 2 | 2017 | 138 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 975 | 0.060 |
Why?
| | Academic Medical Centers | 2 | 2021 | 566 | 0.060 |
Why?
| | Sex Factors | 2 | 2025 | 2136 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1386 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2420 | 0.050 |
Why?
| | Regression Analysis | 2 | 2017 | 1003 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1550 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 224 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 248 | 0.040 |
Why?
| | Replantation | 1 | 2021 | 32 | 0.040 |
Why?
| | Cost Savings | 1 | 2021 | 86 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 53 | 0.040 |
Why?
| | Gastrectomy | 1 | 2023 | 169 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 51 | 0.040 |
Why?
| | Training Support | 1 | 2021 | 35 | 0.040 |
Why?
| | Fingers | 1 | 2021 | 107 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 58 | 0.040 |
Why?
| | Documentation | 1 | 2023 | 204 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 175 | 0.040 |
Why?
| | Hand | 1 | 2021 | 157 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 323 | 0.040 |
Why?
| | Perception | 1 | 2022 | 378 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 233 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 188 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3448 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 126 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 225 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 237 | 0.030 |
Why?
| | Pharmacovigilance | 1 | 2018 | 25 | 0.030 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 337 | 0.030 |
Why?
| | Age of Onset | 1 | 2020 | 568 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 101 | 0.030 |
Why?
| | Mathematical Concepts | 1 | 2018 | 35 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1483 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 54 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 278 | 0.030 |
Why?
| | Mercaptopurine | 1 | 2016 | 15 | 0.030 |
Why?
| | Hip Fractures | 1 | 2018 | 88 | 0.030 |
Why?
| | Prednisone | 1 | 2018 | 230 | 0.030 |
Why?
| | Etanercept | 1 | 2016 | 60 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 3029 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1912 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2110 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 677 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 62 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 765 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 41 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1260 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 994 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 475 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 235 | 0.030 |
Why?
| | Bias | 1 | 2016 | 201 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 676 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 430 | 0.030 |
Why?
| | Weight Loss | 1 | 2021 | 867 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 512 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1794 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 1018 | 0.020 |
Why?
| | Mental Recall | 1 | 2015 | 225 | 0.020 |
Why?
| | Waiting Lists | 1 | 2015 | 268 | 0.020 |
Why?
| | Medicaid | 1 | 2018 | 475 | 0.020 |
Why?
| | Anticoagulants | 1 | 2018 | 751 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2021 | 2017 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 399 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2218 | 0.010 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|